Clinical trial
A Phase 1 Study to Determine the Safety and Tolerability of Continuous Intrathecal Riluzole in Patients With Progressive Ambulatory Amyotrophic Lateral Sclerosis
NCT07093268 is registered in ClinicalTrials.gov with Brain Trust Bio as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study to Determine the Safety and Tolerability of Continuous Intrathecal Riluzole in Patients With Progressive Ambulatory Amyotrophic Lateral Sclerosis
- Lead sponsor
- Brain Trust Bio
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- August 15, 2025
- Completion date
- January 15, 2027
- Enrollment
- 10 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.